disease-modifying antirheumatic drugs
When residual       inflammation remains after maximum doses of single agents, as is usually the       case, combinations of disease-modifying antirheumatic drugs appear to be a       reasonable consideration for many patients.
When residual       inflammation remains after maximum doses of single agents, as is usually the       case, combinations of  @SUBJECT$  appear to be a       reasonable consideration  @PREDICAT$  many  @OBJECT$ .